Calamos Advisors’s Genmab GMAB Stock Holding History

Calamos Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-38,800	Closed	-$1.58M	–	927
2020 Q4	$1.58M	Buy	+38,800	New	+$1.45M	0.01%	657

Other funds holding GMAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Calamos Advisors's GMAB Position: Q1 2021 in Review

Calamos Advisors sold out of Genmab (GMAB) in Q1 2021, closing a stake of 38,800 shares — an estimated $1.58M sold.

Calamos Advisors first reported a position in GMAB in Q4 2020 and held it in 1 quarter. The position peaked at $1.58M in Q4 2020. 209 funds tracked by Wall St. Rank hold GMAB as of Q1 2021.

Calamos Advisors reported no remaining Genmab position as of Q1 2021 after selling out during the quarter.
Calamos Advisors sold 38,800 Genmab shares in Q1 2021, an estimated $1.58M.
Calamos Advisors first reported a position in Genmab in Q4 2020 and held it in 1 quarter.
Calamos Advisors's Genmab position peaked at $1.58M in Q4 2020.
209 funds tracked by Wall St. Rank held Genmab as of Q1 2021.

Based on Calamos Advisors's 13F filing for Q1 2021, filed 12 Apr 2021.